

Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Medicine

journal homepage: www.elsevier.com/locate/apjtm

Document heading doi:

Protective effect of *Cardiospermum halicacabum* leaf extract on glycoprotein components on STZ-induced hyperglycemic ratsChinnadurai Veeramani¹, Khalid S Al-Numair¹, Mohammed A Alsaif¹, Govindasamy Chandramohan¹, Nouf S Al-Numair², Kodukkur Viswanathan Pugalendi^{3*}¹ Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia² Department of Structural and Molecular Biology, University College London, Darwin Building, Gower Street, London, WC1E 6BT³ Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar-608 002. Tamilnadu, India

ARTICLE INFO

Article history:

Received 24 February 2012

Received in revised form 31 March 2012

Accepted 5 April 2012

Available online 20 December 2012

Keywords:

Streptozotocin

Cardiospermum halicacabum leaf extract

Hexose

Hexosamine

Fucose

Sialic acid

ABSTRACT

Objective: To investigate the protective role of *Cardiospermum halicacabum* (*C. halicacabum*) leaf extract on glycoprotein metabolism in streptozotocin (STZ)-induced diabetic rats. **Methods:** Diabetes was induced in male albino Wistar rats by intraperitoneal administration of STZ. The *C. halicacabum* leaf extract (CHE) was administered orally to normal and STZ-diabetic rats for 45 days. The effects of *C. halicacabum* leaf extract (CHE) on plasma and tissue glycoproteins (hexose, hexosamine, fucose and sialic acid) were determined. **Results:** The levels of plasma and tissues glycoproteins containing hexose, hexosamine and fucose were significantly increased in STZ-induced diabetic rats. In addition, the level of sialic acid significantly increased in plasma and liver while decreased in kidney of STZ-induced diabetic rats. After administration of CHE to diabetic rats, the metabolic alteration of glycoprotein reverted towards normal levels. **Conclusions:** The present study indicates that the CHE possesses a protective effect on abnormal glycoprotein metabolism in addition to its antihyperglycemic activity.

1. Introduction

Diabetes mellitus (DM), a chronic disease affecting millions of individuals worldwide, characterized by absolute or relative deficiencies in insulin secretion and/or insulin action associated with chronic hyperglycemia and disturbances of carbohydrate, lipid and protein metabolism. Based on the World Health Organization (WHO) report, the number of diabetic patients is expected to increase from 171 million in year 2000 to 366 million or more by the year 2030 [1]. Hyperglycemia, due to uncontrolled glucose regulation is considered as the causal link between diabetes and diabetic

complications. A number of studies emphasizes that alterations in glucose metabolism leads to hyperglycemia-induced cell damage by four key metabolic pathways, viz., increased polyol pathway flux, increased glycation of proteins (enzymatic or nonenzymatic), increased hexosamine pathway flux and activation of protein kinase C (PKC) isoforms [2]. Among the above stated possibilities, glycosylation of proteins has been the prime subject of much interest. Glycoproteins, a carbohydrate linked protein macromolecules found in the cell surface, serves as the principal component of animal cells. Alterations in glycoprotein level leads to the pathogenesis of diabetes mellitus [3]. Many studies confirm the involvement of glycoprotein in diabetic complications [4]. With increasing severity of diabetes, there is a parallel rise in glycoprotein levels [5]. During diabetes, utilization of glucose by insulin independent pathways leads to the synthesis of glycoprotein which may be a predictor of angiopathic complications [6].

*Corresponding author: Dr. K.V. Pugalendi, M.Sc., M.Phil., Ph.D., Professor and Head, Department of Biochemistry & Biotechnology, Annamalai University, Annamalainagar - 608 002, Tamilnadu, India.

Tel: +91- 4144-238343

Fax: +91- 4144-239141

E-mail: chinnaveeramani@gmail.com

An increase in the biosynthesis and or a decrease in the metabolism of glycoproteins attributed to the deposition of these materials in the basal membrane of pancreatic cells. In recent times, many traditionally important medicinal plants have been tested for their efficacy against impaired glycoprotein levels in diabetes [7,8].

Plants used in traditional medicine to treat diabetes mellitus represent a valuable alternative for the control of this disease. *C. halicacabum* L. (CH) has been used in Chinese medicine for a long time in the treatment of rheumatism, lumbago, nervous diseases, as a demulcent in orchitis and in dropsy [9–11]. Various pharmacological actions of CH have been investigated in animal models [12]. The anti-inflammatory activity of ethanolic extract against inhibits LPS induced COX-2, TNF- α and iNOS expression in RAW264.7 cells [13]. Experimental pharmacological studies have shown the analgesic and vasodepressant activities [14], antipyretic activity against yeast-induced pyrexia in rats [15], antimalarial [16], antioxidant activity [17], suppressing the production of TNF- α and nitric oxide in human peripheral blood mononuclear cells [18, 19] and anti-ulcer activity against ethanol induced gastric ulcer in rats [20]. Our earlier study, reported that methanolic extract of *C. halicacabum* possesses antihyperglycemic and antioxidants potential against STZ-induced diabetic rats [21, 22]. Hence, the current work to investigate the protective role of *C. halicacabum* leaf extract (CHE) on glycoproteins metabolism in STZ-induced diabetic rats.

2. Materials and methods

2.1. Animals

Male albino Wistar rats (weighing 180–200 g, 9 weeks old) were procured from the Central Animal House, Department of Experimental Medicine, Rajah Muthiah Medical College and Hospital, Annamalai University, and maintained in an airconditioned room [(25 \pm 1) °C] with a 12 h light/12 h dark cycle. Feed and water were provided *ad libitum*. The study was conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH, 1985) and the experimental study was approved by the Ethical Committee of Rajah Muthiah Medical College and Hospital (Reg No.160/1999/CPCSEA), Annamalai University, Annamalainagar.

2.2. Chemicals

Streptozotocin was obtained from Sigma–Aldrich Company (St. Louis, Missouri, USA). All other chemicals used were

of analytical grade obtained from E. Merck, Mumbai and HIMEDIA, Mumbai, India.

2.3. Experimental induction of diabetes

The animals were made diabetic by an intraperitoneal injection of streptozotocin (STZ, 40 mg/kg body weight, between 8:00 AM to 9:00 AM) in a freshly prepared citrate buffer (0.1M, pH 4.5) after an overnight fast. STZ injected animals were given 20% glucose solution for 24 h to prevent initial drug-induced hypoglycaemic mortality. The animals exhibited massive glycosuria (determined by Benedict's qualitative test, Benedict 1911) and hyperglycaemia within a few days. Diabetes was confirmed by measuring the fasting blood glucose concentration 96 h after induction[23]. Albino rats with a blood glucose level above 220 mg/dL were considered diabetic and were used in the experiment.

2.4. Plant material

Leaves of *C. halicacabum* were collected from the local areas, Jeyankondam, Ariyalur district, Tamil Nadu, India. The plant was botanically identified and authenticated in the Department of Botany, Annamalai University, Annamalainagar, Chidambaram, Tamil Nadu, India and a voucher specimen was deposited at the herbarium of botany.

2.5. Preparation of plant extract

The plant leaf was shade dried at room temperature [(32 \pm 2) °C] and the dried leaf was ground into fine powder using a pulverizer. The powdered part was sieved and kept in deep freezer until use. 100 g of dry fine powder was suspended in 300 mL of ethanol for 72 h. The extract was filtered using a muslin cloth and concentrated at [(40 \pm 5) °C].

2.6. Experimental design

The animals were randomly divided into five groups of six animals each. In our earlier study, the extract was suspended in 2% gum acacia vehicle solution and fed by intubation at three different doses such as 50, 100 and 200 mg/kg body w.t. The dose of 200 mg exhibited maximum reduction of blood glucose when compared to the other two doses in STZ-induced diabetic rats [22]. The active dose of 200 mg was used in this study.

Group I: Normal (2% gum acacia), Group II: Normal + CHE (200 mg/kg body wt.) in 2% gum acacia, Group III: Diabetic control rats, Group IV: Diabetic + CHE (200 mg/kg body wt.) in 2% gum acacia, Group V: Diabetic + glibenclamide (600 μ g/kg body wt.) in 2% gum acacia.

After 45 days, the animals were anaesthetized using ketamine (24 mg/kg/body weight, intramuscular injection), and sacrificed by cervical dislocation. Between 8:00 am and 9:00 am blood was collected in tubes with a mixture of potassium oxalate and sodium fluoride (1:3) to get plasma for various assays. Tissues (liver and kidney) were collected and stored at 4 °C for the measurement of various parameters.

2.7. Biochemical estimations

Blood glucose was estimated by using the reagent kit method of Trinder [23]. Total hexoses, hexosamine, fucose and sialic acid were estimated by the methods of Niebes [24], Elson and Morgon [25], Dische and Shettles [26] and Welmer *et al* [27], respectively.

2.8. Statistical analysis

Values are given as means±S.D. for six rats in each group. Data were analyzed by one-way analysis of variance followed by Duncan's Multiple Range Test (DMRT) using

SPSS version 10 (SPSS, Chicago, IL). The limit of statistical significance was set at $P \leq 0.05$.

3. Results

Table 1 shows the effect of the 45 day oral administration of CHE on blood glucose levels in normal and STZ-diabetic rats. Diabetic rats showed an elevated blood glucose level and administration of CHE and glibenclamide in diabetic rats showed a decreased blood glucose level.

Table 2 represent the levels of total hexoses and hexosamines in the plasma and tissues (liver and kidney) of normal and diabetic rats. The diabetic rats had increased levels of total hexoses and hexosamines in the plasma and tissues and treatment with CHE and glibenclamide showed reversal of these parameters towards normal levels.

Tables 3 represent the levels of fucose and sialic acid in the plasma and tissues (liver and kidney) of normal and diabetic rats. The diabetic rats had increased levels of fucose and sialic acid (except kidney) in the plasma and tissues while

Table 1

Effect of alcoholic leaf extract of *C. halicacabum* (CHE) on the glucose levels in the plasma of normal and STZ-diabetic rats.

Groups	Glucose (mg/dL)	
	0th day	After 45 days
Normal control (2% gum acacia)	66.54±5.89	74.55±4.34a
Diabetic control	246.63±9.45	290.52±16.24b
Normal + CHE (200 mg/kg body wt.)	72.48±5.52	68.93±3.94a
Diabetes + CHE (200 mg/kg body wt.)	246.37±12.39	138.45±7.10e
Diabetes + glibenclamide (600 µg/kg body wt.)	251.38±17.48	98.50±9.56f

Values are means ± SD of 6 rats from each group, values not sharing a common superscript differ significantly at $P < 0.05$ (DMRT).

Table 2

Effect of CHE on the hexoses and hexosamines in the plasma, liver and kidney of normal and STZ-diabetic rats.

Groups	Hexoses			Hexoseamines		
	Plasma (mg/dL)	Liver (mg/100 g tissue)	Kidney (mg/100 g tissue)	Plasma (mg/dL)	Liver (mg/100 g tissue)	Kidney (mg/100 g tissue)
Normal control (2% gum acacia)	102.27±6.89 ^{af}	22.22±0.78 ^a	20.05±1.11 ^a	45.12±1.17 ^a	8.11±1.94 ^a	5.48±0.49 ^{af}
Diabetic control	165.15±8.46 ^b	41.04±1.101 ^b	38.13±2.66 ^b	65.34±3.53 ^b	20.22±3.09 ^b	14.22±1.26 ^b
Normal + CHE (200 mg/kg body wt.)	99.24±7.83 ^a	20.98±1.15 ^a	18.18±1.07 ^a	43.34±2.27 ^a	7.45±1.76 ^a	4.51±0.21 ^a
Diabetes + CHE (200 mg/kg body wt.)	120.45±5.57 ^c	28.03±1.73 ^c	27.27±2.40 ^c	51.78±1.82 ^c	11.44±2.13 ^d	6.20±0.56 ^c
Diabetes + glibenclamide (600 µg/kg body wt.)	109.00±6.51 ^f	24.24±2.14 ^f	22.98±2.90 ^f	47.89±2.02 ^f	9.33±1.74 ^{ad}	5.19±0.47 ^f

Values are means ± SD of 6 rats from each group, values not sharing a common superscript differ significantly at $P < 0.05$ (DMRT).

Table 3

Effect of CHE on the fucose and sialic acid in the plasma, liver and kidney of normal and STZ-diabetic rats.

Groups	Fucose			Sialic acid		
	Plasma (mg/dL)	Liver (mg/100g tissue)	Kidney (mg/100g tissue)	Plasma (mg/dL)	Liver (mg/100g tissue)	Kidney (mg/100g tissue)
Normal control (2% gum acacia)	8.75±0.81 ^a	14.48±1.35 ^a	11.67±1.08 ^a	42.14±2.63 ^{af}	8.18±0.69 ^a	7.42±0.26 ^a
Diabetic control	15.11±1.16 ^b	27.16±2.46 ^b	25.42±1.94 ^b	67.14±2.02 ^b	17.86±0.88 ^b	2.90±0.16 ^b
Normal + CHE (200 mg/kg body wt.)	7.82±0.60 ^a	13.14±1.08 ^a	10.83±0.68 ^a	40.59±1.77 ^a	7.14±0.67 ^c	8.10±0.31 ^c
Diabetes + CHE (200 mg/kg body wt.)	10.32±0.94 ^d	17.08±1.54 ^c	15.83±1.36 ^c	50.35±2.38 ^e	10.24±0.60 ^f	6.07±0.27 ^c
Diabetes + glibenclamide (600 µg/kg body wt.)	8.91±0.81 ^a	15.83±1.24 ^{ac}	12.36±0.89 ^a	44.10±1.63 ^f	9.05±0.54 ^a	6.98±0.40 ^f

Values are means ± SD of 6 rats from each group, values not sharing a common superscript differ significantly at $P < 0.05$ (DMRT).

treatment with CHE and glibenclamide showed reversal of these parameters towards normal levels.

4. Discussion

Streptozotocin selectively destroys the pancreatic insulin secreting β -cells, leaving less active cells and resulting in a diabetic state [28,29]. The fundamental mechanism underlying hyperglycaemia in diabetes mellitus involves the overproduction (excessive hepatic glycogenolysis and gluconeogenesis) and decreased utilization of glucose by the tissues [30], and studies have shown that the level of blood glucose was elevated in STZ-induced diabetic rats. Hence, in the present study, we observed an increased level of blood glucose. Oral administration of CHE resulted in a significant reduction in blood glucose. Flavonoids are one of the most numerous and widespread groups of phenolic compounds in higher plants [31]. Some of them, due to their phenolic structure are known to be involved in the healing process of free radical mediated diseases including diabetes [32]. The plant leaf possesses several flavonoids such as apigenin, pinitol and luteolin [33], which are reported as the antidiabetic principles. Apigenin, a component of CHE, was also isolated from flowers of *Platycodon grandiflorum* and found to possess an inhibitory effect on the aldose reductase enzyme [34]. This enzyme is known to play a key role in the polyol pathway, by catalyzing the reduction of the glucose to sorbitol, which under normal conditions cannot diffuse out of cell membranes. Because of the intracellular accumulation of sorbitol, the chronic complications (such as neuropathy, retinopathy and cataracts) of diabetes can occur. Apigenin and luteolin were shown to possess antihyperglycaemic [35, 36] and antioxidant activity [36,37].

Glycoproteins are carbohydrate linked protein macromolecules found in the cell surface, which form the principle components of animal cells. They play an important role in membrane transport, cell differentiation and recognition, the adhesion of macromolecules to cell surface and the excretion and absorption of macromolecules [39]. Prolonged elevation of blood glucose in diabetes may result in structural and functional alterations of both circulating and membrane bound proteins [40]. Alterations in the diabetic state of the composition of the carbohydrate components of glycoproteins, especially serum glycoproteins and glycoproteins of the capillary basement membrane have been reported [41].

Protein bound hexoses in the cell membrane provides hydrophobic areas, whereas protein bound hexosamine provides cationic charges on the cell membrane surface and make the membrane more polar. The elevated level of

hexoses in diabetic rats may be associated with disturbances with carbohydrate metabolism. Treatment with CHE and glibenclamide in diabetic rats showed significantly decreased hexoses due to improved glycemic control. Hexosamines function as physiologic glucose sensors that serve as an adaptor in diverting excess calories toward storage as fat [42]. One pathway through which glucose is sensed subacutely is hexosamine synthesis. The amination of fructose-6-phosphate to glucosamine-6-phosphate is rate limiting and is catalysed by glutamine fructose-6-phosphate aminotransferase (GFA) [43]. In accordance with previous report diabetic rats had elevated level of hexosamines, which could be due to, increased expression of GFA and increased plasma glucose. In our report, diabetic rats had elevated level of hexosamine in plasma and tissues when compared with normal rats. Diabetic rats treated with CHE and glibenclamide showed significantly decreased hexosamines in the plasma and tissues when compared to diabetic rats, which could be due to improved glycemic control.

Sialic acid is the terminal residue of the oligosaccharide side chain of glycoproteins and widely occurs in the exposed positions of molecules like hormones, enzymes and also on tissues. Elevated levels of serum sialic acid are considered to be a good predictor of cardiovascular disease [44]. Diabetic rats had increased level of sialic acid in the plasma and tissues [45]. In our study, the level of sialic acid in plasma and tissues of diabetic control rats significantly elevated when compared to normal rats. The elevated level of sialic acid in diabetic rats might be due to either enhanced sialic acid synthesis or decreased sialidase activity. Sialic acid contributes to the negative charges on this membrane, thus possibly playing a role in the selective glomerular permeability to negative charged proteins [46]. It has been postulated that an increased activity of sialidase, an enzyme which catalyses the removal of sialic acid residues from sialoconjugates which might be responsible for the depletion of glomerular sialic acid [47]. Treatment with CHE and glibenclamide had significantly decreased sialic acid in the plasma and tissues of diabetic rats, which could be due to the regulation of sialidase activity by insulin, since insulin is a more likely mediator of sialic acid changes than any other alterations in plasma glucose levels [45].

Fucose (6-deoxy-L-galactose) is a characteristic constituent of many glycoproteins, and is a mobile component of plasma glycoproteins of particular physiological and pathological significance. In our study, diabetic rats had elevated level of fucose, which could be due to elevated blood glucose level, which is in line with previous report [45]. Treatment with CHE and glibenclamide in diabetic rats had significantly decreased fucose levels,

which could be due to improved glycemic control.

The biosynthesis of the carbohydrate moieties of glycoprotein forms the insulin independent pathways for the use of glucose 6–phosphate. But the deficiency of insulin during diabetes produces derangement of glycoprotein metabolism, resulting in the thickening of the basal membrane of pancreatic beta cells. In hyperglycemic state, the excess availability of glucose accelerates the synthesis of glucose basement membrane components i.e., glycoproteins [47]. Agents with antioxidant or free radical scavenging property may inhibit oxidative reactions associated with glycation. In this context, previous studies have shown that decrease in hyperglycemia could lead to a decrease in glycoprotein levels [45]. Administration of CHE to diabetic rats resulted in a significant reversal of all these changes to near normal.

In conclusion, the decreased hyperglycemic state in CHE treated diabetic rats might have been responsible for the decrease of glycoproteins in plasma, liver and kidney. The observed effect of CHE on reversing the adverse effects of hyperglycemia provides an insight into the pathogenesis of diabetic complications, and may be used to advantage in therapeutic approaches.

Conflict of interest statement

There are no conflicts of interest.

Acknowledgments

The support was provided from the National Nutrition Policy Chair, King Saud University, Riyadh, Saudi Arabia is gratefully acknowledged.

References

- [1] Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010; **87**: 4–14.
- [2] Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. *Toxicol Appl Pharmacol* 2006; **212**: 167–178.
- [3] Michael J, Fowler MD. Microvascular and macrovascular complications of diabetes. *Clin Diabetes* 2008; **26**: 2.
- [4] Ramkumar KM, Rajaguru P, Latha M, Ananthan R. Ethanol extract of *Gymnema montanum* leaves reduces glycoprotein components in experimental diabetes. *Nut Res* 2007; **27**: 97–103.
- [5] Gul Memon A, Rahman A, Ahmed N. Serum glycoproteins in diabetic and non–diabetic patients with and without cataract. *Pak J Ophthalmol* 2008; **24**: 3.
- [6] Neerati P, Barla R, Bedada S. Influence of diabetes mellitus on P–glycoprotein function in rat intestine. *Pharmacologia* 2011; **2**(10): 293–298.
- [7] Sulaiman GM, Al–Amiery AAH, Mohammed AA, Al–Temimi AA. The effect of cherry sticks extract on the levels of glycoproteins in alloxan–induced experimental diabetic mice. *Ann Clin Lab Sci Winter* 2012; **42**: 34–41.
- [8] Suganya S, Narmadha R, Gopalakrishnan VK, Devaki K. Hypoglycemic effect of *Costus pictus* D. Don on alloxan induced type 2 diabetes mellitus in albino rats. *Asian Pac J Trop Biomed* 2012; **2**(2): 117–123
- [9] Sadique J, Chandra T, Thenmozhi V, Elango V. Biochemical modes of action of *Cassia occidentalis* and *Cardiospermum halicacabum* in inflammation. *J Ethnopharmacol* 1987; **19**: 01–212.
- [10] Chandra T, Sadique J. Anti–arthritic effect of *Cardiospermum halicacabum* in rats. *Indian Med* 1989; **1**: 12–20.
- [11] Rao NV, Prakash KC, Shanta Kumar SM. Pharmacological investigation of *Cardiospermum halicacabum* L. in different animal models of diarrhoea. *Indian J Pharmacol* 2006; **38**: 346–349.
- [12] Govindarajan M, Sivakumar R. Repellent properties of *Cardiospermum halicacabum* Linn. (Family: Sapindaceae) plant leaf extracts against three important vector mosquitoes. *Asian Pac J Trop Biomed* 2012; **2**(8): 602–607
- [13] Sheeba MS, Asha VV. *Cardiospermum halicacabum* ethanol extract inhibits LPS induced COX–2, TNF–alpha and iNOS expression, which is mediated by NF–kappa B regulation, in RAW264.7 cells. *J Ethnopharmacol* 2009; **124**: 39–44.
- [14] Gopalakrishnan C, Dhananjayan R, Kameswaran L. Studies on the pharmacological actions of *Cardiospermum halicacabum*. *Indian Physiol Pharmacol* 1976; **20**: 203–206.
- [15] Asha VV, Pushpangadan P. Antipyretic activity of *Cardiospermum halicacabum*. *Indian J Exp Biol* 1999; **37**: 411–414.
- [16] Waako PJ, Gumede B, Smith P, Folb PI. The in vitro and in vivo antimalarial activity of *Cardiospermum halicacabum* L. and *Momordica foetida* Schumch. *Et Thonn J Ethnopharmacol* 2005; **99**: 137–143.
- [17] Kumaran A, Karunakaran RJ. Antioxidant activities of the methanol extract of *Cardiospermum halicacabum*. *Pharm Biol* 2006; **44**: 146–151.
- [18] Venkatesh Babu KC, Krishnakumari S. *Cardiospermum halicacabum* suppresses the production of TNF–alpha and NO by human peripheral blood mononuclear cells. *African J Biomed Res* 2006; **9**: 95–99.
- [19] Thabrew I, Munasinghe J, Chackrewarthy S, Senarath S. The effects of *Cassia auriculata* and *Cardiospermum halicacabum* teas on the steady state blood level and toxicity of carbamazepine. *J Ethnopharmacol* 2004; **90**: 145–150.
- [20] Sheeba MS, Asha VV. Effect of *Cardiospermum halicacabum* on ethanolinduced gastric ulcers in rats. *J Ethnopharmacol* 2006;

- 106:** 105–110.
- [21]Veeramani C, Pushpavalli G, Pugalendi KV. Antihyperglycaemic effect of *Cardiospermum halicacabum* Linn. leaf extract on STZ-induced diabetic rats. *J Appl Biomed* 2008; **6**: 19–26.
- [22]Veeramani C, Pushpavalli G, Pugalendi KV. *In vivo* antioxidant and hypolipidemic effect of *Cardiospermum halicacabum* leaf extract in streptozotocin-induced diabetic rats. *J Basic Clin Physiol Pharmacol* 2010; **21**(2): 107–125.
- [23]Trinder P. Determination of blood glucose using an oxidase peroxidase system with a non-carcinogenic chromogen. *J Clin Pathol* 1969; **22**: 158–161.
- [24]Niebes P. Determination of enzymes and degradation products of glycosaminoglycan metabolism in the serum of healthy and various subjects. *Clin Chim Acta* 1972; **42**: 399–408.
- [25]Elson LA, Morgon WT. A Colorimetric method for the determination of glucosamine and galactosamine. *Biochem J* 1933; **27**: 1824–1828.
- [26]Dische Z, Shettles LB. Special colorimetric reaction of methyl pentoses and a spectrophotometric micromethod for their determination. *J Biol Chem* 1948; **175**: 595–604.
- [27]Welmer HE, Moshine JR, Sailcin D. Distribution of glycoproteins in normal human plasma. *Am Rev Tuberc* 1952; **68**: 594.
- [28]Lenzen S. The mechanisms of alloxan and streptozotocin-induced diabetes. *Diabetologia* 2008; **51**(2): 216–226.
- [29]Suresh Kumar RB, Kar B, Dolai N, Bala A, Kanti P. Evaluation of antihyperglycemic and antioxidant properties of *Streblus asper* Lour against streptozotocin-induced diabetes in rats. *Asian Pac J Trop Biomed* 2012; **2**(2): 139–143
- [30]Toft I, Jenssen T. Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production. *Scand J Clin Lab Invest* 2005; **65**(4): 307–320.
- [31]Jin Dai J, Mumper RJ. Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. *Molecules* 2010; **15**: 7313–7352.
- [32]Yao Y, Cheng X, Wang L, Wang S, Ren G. Major phenolic compounds, antioxidant capacity and antidiabetic potential of rice bean (*Vigna umbellata* L.) in China. *Int J Mol Sci* 2012; **13**: 2707–2716.
- [33]Kumar R, Muruganathan G, Nandakumar K, Talwar S. Isolation of anxiolytic principle from ethanolic root extract of *Cardiospermum halicacabum*. *Phytomedicine* 2011; **18**: 219–223.
- [34]Jang DS, Lee YM, Jeong IH, Kim JS. Constituents of the flowers of *Platycodon grandiflorum* with inhibitory activity on advanced glycation end products and rat lens aldose reductase in vitro. *Arch Pharm Res* 2010; **33**(6): 875–880.
- [35]Li W, Dai RJ, Yu YH, Li L, Wu CM, Luan WW, et al. Antihyperglycemic effect of *Cephalotaxus sinensis* leaves and GLUT-4 translocation facilitating activity of its flavonoid constituents. *Biol Pharm Bull* 2007; **30**(6): 1123–1129.
- [36]Ding L, Jin D, Chen X. Luteolin enhances insulin sensitivity via activation of PPAR γ transcriptional activity in adipocytes. *J Nutr Biochem* 2010; **21**(10): 941–947.
- [37]Patel DK, Kumar R, Laloo D, Hemalatha S. Natural medicines from plant source used for therapy of diabetes mellitus: An overview of its pharmacological aspects. *Asian Pac J Trop Biomed* 2012; **2**(3): 239–250
- [38]Akroum S, Bendjeddou D, Satta D, Lalaoui K. Antibacterial, antioxidant and acute toxicity tests on flavonoids extracted from some medicinal plants. *Int J Green Pharm* 2010; **4**: 165–169.
- [39]Parillo F, Arias MP, Supplizi AV. Glycoprofile of the different cell types present in the mucosa of the horse guttural pouches. *Tissue Cell* 2009; **41**(4): 257–265.
- [40]Ciftci G, Yarim GF. Evaluation of IGF-I levels and serum protein profiles of diabetic cats and dogs. *J Vet Sci* 2011; **12**(4): 325–331.
- [41]Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. *Am J Physiol Endocrinol Metab* 2006; **290**: E1–E8.
- [42]Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: A nutritional perspective of diabetes, obesity, and cancer. *Sci STKE* 2006; **346**: re7.
- [43]Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. *Genes Dev* 2010; **24**(24): 2784–2799.
- [44]Lebensohn N, Re A, Carrera L, Barberena L, D'Arrigo M, Foresto P. Serum sialic acid, cellular anionic charge and erythrocyte aggregation in diabetic and hypertensive patients. *Medicina (B Aires)* 2009; **69**(3): 331–334.
- [45]Saravanan G, Ponnuragan P, Senthil Kumar GP, Rajarajan T. Antidiabetic effect of S-allylcysteine: Effect on plasma and tissue glycoproteins in experimental diabetes. *Phytomedicine* 2010; **17**(14): 1086–1089.
- [46]Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH. Glomerular filtration is normal in the absence of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. *Nephrol Dial Transplant* 2009; **24**(7): 2044–2051.
- [47]Ghassan MS, Ahmed AHA, Abbas AM, Ali AAT. The effect of cherry sticks extract on the levels of glycoproteins in alloxan-induced experimental diabetic mice. *Ann Clin Lab Sci Winter* 2012; **42**: 34–41.